(c) and (d) The details are given below:—

Name of Items	Name(s) of Prodcer	Period					
		1987-88		1988-89		1989-90	
		Prodn.	Import	Prodn.	Import	Prodn.	Import
Carbamezapine	S.G. Chem.	..	19.575 MT	237 Kg.	22.085 MT	..	28.4 MT
Diclofenac Sodium	Hindustan Ciba-Geigy	*	—	*	3.649 MT	*	8.36 MT

*Production not minotored.

(e) Yes, Sir.

(f) The landed prices of thes bulk drugs considered in fixing the prices of the concerned finished medicines are as under:—

Sl. No.	Name of bulk drug	Landed price Rs. per Kg.
1.	Carbamezapine	4582.38
2.	Diclofenac Sodium	3144.28

Since landed cost of each drug is computed on the basis of total annual imports, the present CIF cost and landed cost are not available.

Assessment of oxytetracycline of M/s. PFIZER

2079. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to refer to the answer to Unstared Question 650 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) what is the quantity of Oxytetracycline in respect of which assessment of M/s. Pfizer upto December, 1983 is based;

(b) when the liability of M/s. Merind was communicated to that company and what are the reasons for non recovery of even single penny form that company;

(c) whether the recovery in respect of M/s. Ethnor final is made;

(d) if not, what is the position;

(e) whether it is a fact that assessment in respect of xylocine formulation of S. G. Pharmeceuticals have not been made by the Special Team; and

(f) if so, the reasons thereof and by when the assessment would be made?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The revised assessment of Rs. 87.61 lakhs as the tentative liability of M/s. Pfizer is related to the various Oxytetracycline formulations covering the period April 1981 to August 1982. The exact quantity of the bulk drug has yet to be computed because it has been consumed for other formulations also, such as Veterinary formulatins...

(b) The total tentative liability of Rs. 22.80 crores, covering the period upto 1986, was communicated to M|s. Merind by February 1991. Recently, the company requested for an opportunity to explain their points of view personally to the authorities in this Deptt.

(c) and (d) The recovery of Rs. 10.19 lakhs, in the case of M|s. Ethnor is final for the period upto Dec. 83. Data for the subsequent period is still awaited from the company, on the receipt of which further liability, if any will be determined.

(e) and (f) The representation of M|s. Ambalal Sarabhai Enterprises (for S. G.

Pharmaceuticals) against the tenative liability of Rs. 205.36 lakhs for the period upto 31.12.83, already communicated to it, is under consideration and the final decision will be communicated soon. The data for the subsequent period is still awaited from the company.

Duty conctssions on bulk drugs and formulations

2080. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 566 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) what are the names of bulk drugs or formulations where the objective has been achieved based on duty concession granted by Government during the last three years;

(b) what are the names of Bulk drugs which are being produced from Basic stage and names of imported formulations being indigenously produced after grant of duty concessions;

(c) whether duty concessions have any bearing on the price structure of price controlled and decontrolled bulk drug and formulations; and

(d) if so, what are the names of those bulk drugs and formulations where prices have been reduced linked to Custom Duty reduction effected by Governmen during the last three years including the current year?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) The names of bulk drugs and drug intermediates on which customs duty concessions have been given by the Ministry of Finance during the last three years are given in the customs notifications published from time to time in the official Gazette, copies of which are available in the Parliament Library. Proposals of customs duty concessions are examined in this Deptt. before sending any recommendation in this regard to Ministry of Finance. The recommendation as finally accepted by the Ministry of Finance are taken into account while fixing the price of controlled bulk drugs and formulations Major objective of duty rationalisaton to encourage production from a mor basic stage. This reduction in duty is no linked necessarily in every case to reduc tion in prices of bulk drugs and formula tions.

Abolition of loan licensing system in Pharmaceuticals

2081. SHRI SURESH KALMADI: Wi the PRIME MINISTER be pleased t state:

(a) whether it is a fact that loan licer sing system in pharmaceuticals is propose to be abolished from 31st December, 199

(b) if so, the reasons therefor;

(c) the number of persons who woul be affected by abolition of this system an how they would be rehabilitated; and

(d) whether this abolition affect the ove all availability of drugs in the country?

THE MINISTER OF STATE IN TH MINISTRY OF CHEMICALS AND FEI TILIZERS (SHRI CHINTA MOHAN

(a) to (d) The matter regarding discor tinuation of loan licence system fro 1-1-1992 is being re-examined comprehei sively in the light of representations/su gestions received in this regard from th manufacturers/drug industry association

Wrong exclusion of bulk drugs Kelkar Committee

2082. SHRIMATI BIJOYA CHAI RAVARTY: Will the PRIME MINISTE be pleased to refer to the answer t Unstarred Question 688 given in th Rajya Sabha on the 5th Septembe 1991 and state:

(a) what are the details of represen tations received by Government again wrong exclusion of bulk drugs by Kelka Committee;

(b) when each of the representation was received and from whom;

(c) when did the committee conside the representations and what were th